Arginase inhibition by piceatannol-3'-O-β-D-glucopyranoside improves endothelial dysfunction via activation of endothelial nitric oxide synthase in ApoE-null mice fed a high-cholesterol diet

Woo,Ainieng; Shin,Woosung; Cuong,To  Dao; Min,Byungsun; Lee,Jeong  Hyung; Jeon,Byung  Hwa; Ryoo,Sungwoo

doi:10.3892/ijmm.2013.1261

Arginase inhibition by piceatannol-3'-O-β-D-glucopyranoside improves endothelial dysfunction via activation of endothelial nitric oxide synthase in ApoE-null mice fed a high-cholesterol diet

Authors:
- Ainieng Woo
- Woosung Shin
- To Dao Cuong
- Byungsun Min
- Jeong Hyung Lee
- Byung Hwa Jeon
- Sungwoo Ryoo
View Affiliations

Affiliations: Department of Biology, Kangwon National University, Chuncheon 200-701, Republic of Korea, College of Pharmacy, Catholic University, Daegu 712-702, Republic of Korea, Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chuncheon 200-701, Republic of Korea, Department of Physiology, School of Medicine, Chungnam National University, Daejeon 301-131, Republic of Korea
Published online on: January 30, 2013 https://doi.org/10.3892/ijmm.2013.1261
Pages: 803-810

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Elevated plasma cholesterol is a hallmark of numerous cardiovascular diseases that are closely linked to endothelial dysfunction indicating decreased nitric oxide (NO) production in the endothelium. It has been previously demonstrated that piceatannol-3'-O-β-D-glucopyranoside (PG) inhibits arginase activity and reciprocally regulates NO production. Here, we aimed to ascertain whether PG ameliorates vascular function in wild-type (WT) and atherogenic model mice [apolipoprotein E-null mice (ApoE-/-)] and to investigate the possible underlying mechanism. Preincubation of aortic vessels from WT mice fed a normal diet (ND) with PG attenuated vasoconstriction response to U46619 and phenylephrine (PE), while the vasorelaxant response to acetylcholine (Ach) was markedly enhanced in an endothelium-dependent manner. However, the endothelium-independent NO donor, sodium nitroprusside (SNP), did not change vessel reactivity. In thoracic aorta from ApoE-/- mice, a high-cholesterol diet (HCD) induced an increase in arginase activity, a decrease in NO release and an increase in reactive oxygen species generation that was reversed by treatment with PG. The effect of PG was associated with enhanced stability of the eNOS dimer and was not dependent on the expression levels of arginase II and eNOS proteins, although eNOS expression was increased in ApoE-/- mice fed an HCD. Furthermore, PG treatment attenuated the PE-dependent contractile response, and significantly improved the Ach-dependent vasorelaxation response in aortic rings from ApoE-/- mice fed an HCD. On the other hand, PG incubation neither altered the contractile response to a high K+ solution nor the relaxation response to SNP. When analyzing the L-arginine content using high-performance liquid chromatography, PG incubation increased the intracellular L-arginine concentration. PG administration in the drinking water significantly reduced fatty streak formation in ApoE-/- mice fed an HCD. These data indicate that PG improves the pathophysiology of cholesterol-mediated endothelial dysfunction. Therefore, we conclude that the development of PG as a novel effective therapy for preventing atherosclerotic diseases is warranted.

View Figures

View References

1	Moncada S and Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med. 329:2002–2012. 1993. View Article : Google Scholar : PubMed/NCBI
2	Ryoo S, Lemmon CA, Soucy KG, et al: Oxidized low-density lipoprotein-dependent endothelial arginase II activation contributes to impaired nitric oxide signaling. Circ Res. 99:951–960. 2006. View Article : Google Scholar : PubMed/NCBI
3	Ryoo S, Gupta G, Benjo A, et al: Endothelial arginase II: a novel target for the treatment of atherosclerosis. Circ Res. 102:923–932. 2008. View Article : Google Scholar : PubMed/NCBI
4	Matsuda H, Morikawa T, Toguchida I, Park JY, Harima S and Yoshikawa M: Antioxidant constituents from rhubarb: structural requirements of stilbenes for the activity and structures of two new anthraquinone glucosides. Bioorg Med Chem. 9:41–50. 2001. View Article : Google Scholar : PubMed/NCBI
5	Choi SZ, Lee SO, Jang KU, et al: Antidiabetic stilbene and anthraquinone derivatives from Rheum undulatum. Arch Pharm Res. 28:1027–1030. 2005. View Article : Google Scholar : PubMed/NCBI
6	Moon MK, Kang DG, Lee JK, Kim JS and Lee HS: Vasodilatory and anti-inflammatory effects of the aqueous extract of rhubarb via a NO-cGMP pathway. Life Sci. 78:1550–1557. 2006. View Article : Google Scholar : PubMed/NCBI
7	Ngoc TM, Minh PT, Hung TM, et al: Lipoxygenase inhibitory constituents from rhubarb. Arch Pharm Res. 31:598–605. 2008. View Article : Google Scholar : PubMed/NCBI
8	Choi KH, Kim JE, Song NR, et al: Phosphoinositide-3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells. Cardiovasc Res. 85:836–844. 2010. View Article : Google Scholar : PubMed/NCBI
9	Woo A, Min B and Ryoo S: Piceatannol-3′-O-beta-D-glucopyranoside as an active component of rhubarb activates endothelial nitric oxide synthase through inhibition of arginase activity. Exp Mol Med. 42:524–532. 2010.
10	White AR, Ryoo S, Li D, et al: Knockdown of arginase I restores NO signaling in the vasculature of old rats. Hypertension. 47:245–251. 2006. View Article : Google Scholar : PubMed/NCBI
11	Boger RH, Bode-Boger SM, Mugge A, et al: Supplementation of hypercholesterolaemic rabbits with L-arginine reduces the vascular release of superoxide anions and restores NO production. Atherosclerosis. 117:273–284. 1995. View Article : Google Scholar : PubMed/NCBI
12	Berkowitz DE, White R, Li D, et al: Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels. Circulation. 108:2000–2006. 2003. View Article : Google Scholar : PubMed/NCBI
13	Santhanam L, Lim HK, Miriel V, et al: Inducible NO synthase dependent S-nitrosylation and activation of arginase1 contribute to age-related endothelial dysfunction. Circ Res. 101:692–702. 2007. View Article : Google Scholar : PubMed/NCBI
14	Maarsingh H, Zaagsma J and Meurs H: Arginase: a key enzyme in the pathophysiology of allergic asthma opening novel therapeutic perspectives. Br J Pharmacol. 158:652–664. 2009. View Article : Google Scholar : PubMed/NCBI
15	Christianson DW: Arginase: structure, mechanism, and physiological role in male and female sexual arousal. Acc Chem Res. 38:191–201. 2005. View Article : Google Scholar : PubMed/NCBI
16	Yang Z and Ming XF: Endothelial arginase: a new target in atherosclerosis. Curr Hypertens Rep. 8:54–59. 2006. View Article : Google Scholar : PubMed/NCBI
17	Wilson AM, Harada R, Nair N, Balasubramanian N and Cooke JP: L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation. 116:188–195. 2007. View Article : Google Scholar : PubMed/NCBI
18	Walker HA, McGing E, Fisher I, et al: Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol. 38:499–505. 2001. View Article : Google Scholar
19	Blum A, Hathaway L, Mincemoyer R, et al: Oral L-arginine in patients with coronary artery disease on medical management. Circulation. 101:2160–2164. 2000. View Article : Google Scholar : PubMed/NCBI
20	Ansel GM and Lumsden AB: Evolving modalities for femoropopliteal interventions. J Endovasc Ther. 16(Suppl 2): II82–II97. 2009. View Article : Google Scholar : PubMed/NCBI
21	Ichinose F, Roberts JD Jr and Zapol WM: Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 109:3106–3111. 2004. View Article : Google Scholar : PubMed/NCBI
22	Griffiths MJ and Evans TW: Inhaled nitric oxide therapy in adults. N Engl J Med. 353:2683–2695. 2005. View Article : Google Scholar : PubMed/NCBI
23	Barbato JE, Kibbe MR and Tzeng E: The emerging role of gene therapy in the treatment of cardiovascular diseases. Crit Rev Clin Lab Sci. 40:499–545. 2003. View Article : Google Scholar : PubMed/NCBI
24	Kibbe MR and Tzeng E: Nitric oxide synthase gene therapy in vascular pathology. Semin Perinatol. 24:51–54. 2000. View Article : Google Scholar : PubMed/NCBI
25	Ibengwe JK and Suzuki H: Changes in mechanical responses of vascular smooth muscles to acetylcholine, noradrenaline and high-potassium solution in hypercholesterolemic rabbits. Br J Pharmacol. 87:395–402. 1986. View Article : Google Scholar : PubMed/NCBI
26	Arthur JF, Yin ZL, Young HM and Dusting GJ: Induction of nitric oxide synthase in the neointima induced by a periarterial collar in rabbits. Arterioscler Thromb Vasc Biol. 17:737–740. 1997. View Article : Google Scholar : PubMed/NCBI
27	Rupin A, Behr D and Verbeuren TJ: Increased activity of guanylate cyclase in the atherosclerotic rabbit aorta: role of non-endothelial nitric oxide synthases. Br J Pharmacol. 119:1233–1238. 1996. View Article : Google Scholar : PubMed/NCBI
28	Kawashima S: The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Endothelium. 11:99–107. 2004. View Article : Google Scholar : PubMed/NCBI
29	Ozaki M, Kawashima S, Yamashita T, et al: Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice. J Clin Invest. 110:331–340. 2002. View Article : Google Scholar : PubMed/NCBI
30	Shi W, Wang X, Shih DM, Laubach VE, Navab M and Lusis AJ: Paradoxical reduction of fatty streak formation in mice lacking endothelial nitric oxide synthase. Circulation. 105:2078–2082. 2002. View Article : Google Scholar : PubMed/NCBI
31	Closs EI, Scheld JS, Sharafi M and Forstermann U: Substrate supply for nitric-oxide synthase in macrophages and endothelial cells: role of cationic amino acid transporters. Mol Pharmacol. 57:68–74. 2000.PubMed/NCBI
32	Simon A, Plies L, Habermeier A, Martine U, Reining M and Closs EI: Role of neutral amino acid transport and protein breakdown for substrate supply of nitric oxide synthase in human endothelial cells. Circ Res. 93:813–820. 2003. View Article : Google Scholar : PubMed/NCBI
33	Erdely A, Kepka-Lenhart D, Salmen-Muniz R, et al: Arginase activities and global arginine bioavailability in wild-type and ApoE-deficient mice: responses to high fat and high cholesterol diets. PLoS One. 5:e152532010. View Article : Google Scholar : PubMed/NCBI